
CLAIMS

1. An RNAi agent for inhibiting expression of an ANGPTL3 gene, comprising:

an antisense strand that consists of the modified nucleotide sequence of (5′ → 3′) usAfscsUfgAfuCfaAfaUfaUfgUfuGfaGfsc (SEQ ID NO:2), and

a sense strand that consists of the sequence of (5′ → 3′) (NAG37)s(invAb)sgcucaacaUfAfUfuugaucaguas(invAb) (SEQ ID NO:300);

wherein a is 2′-O-methyl adenosine; c is 2′-O-methyl cytidine; g is 2′-O-methyl guanosine; u is 2′-O-methyl uridine, Af is 2′-fluoro adenosine, Cf is 2′-fluoro cytidine; Gf is 2′-fluoro guanosine; Uf is 2′-fluoro adenosine; s is a phosphorothioate linkage; (invAb) is an inverted abasic deoxyribose residue; and (NAG37)s has the following chemical structure:



2. A pharmaceutically acceptable salt of the RNAi agent of claim 1.

3. The pharmaceutically acceptable salt of claim 2, wherein the pharmaceutically acceptable salt is a sodium salt.

4. A pharmaceutical composition comprising the RNAi agent of claim 1 and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable excipient comprises saline.

6. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable excipient comprises water for injection.

7. The pharmaceutical composition of claim 6 further comprising a pharmaceutically acceptable buffering agent.

8. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable excipient comprises buffered saline.

9. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is packaged in a pre-filled syringe.

10. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is packaged in a vial.